BSEBoard Meeting6d ago · 27 Aug 2026, 08:24 pm

Asston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 ,inter alia, to consider and approve 1. Appointment of M/s ....

Asston Pharmaceuticals Ltd · 544445

✦ AI SummaryMgmt Change

Asston Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 04/09/2026 to consider and approve various matters, including the appointment of a new statutory auditor, increase in remuneration of directors, and the date and draft notice of the 7th Annual General Meeting.

Analysis Scores

Earnings Impact2/10
Growth Catalyst3/10
Governance Concern4/10
Regulatory Risk2/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Asston Pharmaceuticals Ltd - 544445 - Board Meeting Intimation for Convening 7Th Annual General Meeting Of The Company

Attachments (1)

📄

a31fb08b-2352-4daa-9c70-cb228adabff9.pdf

pdf

Download →
View document text
ASSTON PHARMACEUTICALS LIMITED (FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED) To, Date: 27th August, 2026 BSE Limited Listing / Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, 400001 BSE Code: 544445 ISIN: INE0SJX01015 Sub: Board Meeting Intimation under Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Dear Sir/ Madam, Pursuant to Regulation 29(1) of the SEBI Listing Regulations, we wish to inform you that a Meeting of the Board of Directors (the "Board") of the Company will be held on Friday, 04th September, 2026, to consider and approve the following matters: 1. To consider and approve the appointment of M/s Panchal S K & Associates (Peer Review Certificate No.: 018089 and Firm Registration No.: 145989W) as Statutory Auditor of the Company; 2. To consider and ascertain the directors retiring by rotation; 3. To consider and approve an increase in remuneration of Mr. Ashish Narayan Sakalkar Din 06601011, Managing Director of the Company; 4. To consider and approve an increase in remuneration of Mrs. Saili Jayaram More Din 02691527, Whole Time Director and CEO of the Company; 5. To consider and approve an increase in remuneration of Mr. Sachin Chandrakant Badakh Din 08685214, Non-Executive Director of the Company; 6. To consider and approve the date and draft notice of the 7th Annual General Meeting of the Company; 7. Other incidental matters Kindly take the same on your records. Thanking you, For and on behalf of the Board of Directors Rishi Upadhaya Company Secretary & Compliance Officer A74324 CIN: U24304MH2019PLC324187 Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com Web: www.asstonpharmaceuticals.com